专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20020098487A1 Materials and methods for detecting fungi 审中-公开
标题翻译：用于检测真菌的材料和方法
公开(公告)号：US20020098487A1
公开(公告)日：2002-07-25
申请号：US09809323
申请日：2001-03-16
申请人： SS Pharmaceutical Co., Ltd.
发明人： Koji Yokoyama , Li Wang
IPC分类号： C12Q001/68 , C07H021/04
CPC分类号： C12Q1/6895
摘要： Nucleic acids for detecting fungi, which have sequences shown in SEQ ID NOs. 3, 57 to 75 are disclosed. The nucleic acids for detecting fungi may be used as probes or primers for gene amplification. In case of using them as primers, detection and identification of fungi belonging to the genus Aspergillus may be attained because the sizes of the amplified nucleic acid fragments vary depending on the species of the fungi belonging to the genus Aspergillus if the primers are appropriately selected.
摘要翻译：用于检测真菌的核酸，其具有SEQ ID NO： 3，57〜75。用于检测真菌的核酸可以用作用于基因扩增的探针或引物。在使用它们作为引物的情况下，可以获得属于曲霉属的真菌的检测和鉴定，因为如果适当选择引物，扩增的核酸片段的大小根据属于曲霉属的真菌的种类而变化。

2. 发明授权

US6103538A Colloidal gold immunoassay method 失效
标题翻译：胶体金免疫测定法
公开(公告)号：US6103538A
公开(公告)日：2000-08-15
申请号：US973747
申请日：1997-12-22
申请人： Takeshi Kotsugai
发明人： Takeshi Kotsugai
IPC分类号： G01N33/553 , G01N21/77 , G01N33/53 , G01N33/532 , G01N33/577 , G01N33/58 , G01N33/533
CPC分类号： G01N33/585 , G01N33/5306 , G01N33/532 , Y10S435/962 , Y10S436/826 , Y10T436/2525
摘要： Disclosed herein is a method for the detection of a target substance by a colloidal gold immunoassay, which comprises dissolving in an immunoreaction system a metal salt selected from the group consisting of sodium, potassium and lithium fluorides, sodium, potassium, lithium and magnesium iodides, sodium, potassium, lithium and magnesium bromides, lithium and magnesium chlorides, sodium, potassium, lithium and magnesium nitrates, sodium, potassium, lithium and magnesium sulfates, sodium, potassium, lithium and magnesium formates, sodium, potassium, lithium and magnesium acetates, and mixtures of at least two of these metal salts, whereby the metal salt is allowed to exist in a reaction mixture.
摘要翻译： PCT No.PCT / JP96 / 01446 Sec。 371 1997年12月22日第 102（e）日期1997年12月22日PCT提交1996年5月29日PCT公布。公开号WO97 / 01099 日期1997年1月9日公开是通过胶体金免疫测定法检测目标物质的方法，其包括在免疫反应系统中溶解选自钠，钾和氟化锂，钠，钾，锂和镁的碘化物，钠，钾，锂和镁的溴化物，氯化锂和氯化镁，硝酸钠，钾，锂和镁，硫酸钠，钾，锂和镁，钠，钾，锂和镁的甲酸钠，锂和镁的乙酸酯，以及这些金属盐中的至少两种的混合物，由此使金属盐存在于反应混合物中。

3. 发明授权

US5939448A Triazole derivative or salt thereof 失效
标题翻译：三唑衍生物或其盐
公开(公告)号：US5939448A
公开(公告)日：1999-08-17
申请号：US872159
申请日：1997-06-10
申请人： Minoru Tokizawa , Sunao Takeda , Yasushi Kaneko , Hiromichi Eto , Kazuya Ishida , Kazunori Maebashi , Masaru Matsumoto , Takemitsu Asaoka , Susumu Sato , Hideaki Matsuda
发明人： Minoru Tokizawa , Sunao Takeda , Yasushi Kaneko , Hiromichi Eto , Kazuya Ishida , Kazunori Maebashi , Masaru Matsumoto , Takemitsu Asaoka , Susumu Sato , Hideaki Matsuda
IPC分类号： C07D249/08 , C07D303/34 , C07D521/00 , A61K31/41
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D303/34
摘要： Described is a triazole derivative represented by the formula (1): wherein R represents a hydrogen atom, an alkyl group, an aralkyl group or an acyl group, n stands for 0 to 2 and m stands for 1 to 5 or salt thereof, and a pharmaceutical containing the derivative or salt as an effective ingredient.
摘要翻译：描述了由式（1）表示的三唑衍生物：其中R表示氢原子，烷基，芳烷基或酰基，n表示0至2，m表示1至5或其盐，含有衍生物或盐作为有效成分的药物。

4. 发明授权

US5935977A Substituted vinyl pyridine derivative and drugs containing the same 失效
标题翻译：取代的乙烯基吡啶衍生物和含有它的药物
公开(公告)号：US5935977A
公开(公告)日：1999-08-10
申请号：US68986
申请日：1998-05-26
申请人： Kazuo Yamazaki , Yoichiro Ogawa , Hidehiko Kohya , Tadashi Mikami , Noriyuki Kawamoto , Noriaki Shioiri , Hiroshi Hasegawa , Susumu Sato
发明人： Kazuo Yamazaki , Yoichiro Ogawa , Hidehiko Kohya , Tadashi Mikami , Noriyuki Kawamoto , Noriaki Shioiri , Hiroshi Hasegawa , Susumu Sato
IPC分类号： C07D213/69 , C07D401/06 , C07D405/12 , C07D405/14 , C07D409/06 , C07D417/14 , A61K31/44
CPC分类号： C07D213/69 , C07D401/06 , C07D405/12 , C07D405/14 , C07D409/06 , C07D417/14
摘要： The present invention relates to a substituted vinylpyridine derivative represented by the following formula (1): ##STR1## (wherein R.sup.1 represents a hydrogen atom, an alkyl group, etc., R.sup.2 represents an alkyl group; one of R.sup.3 and R.sup.4, which are different from each other, represents a hydrogen atom and the other represents a nitrile group, R.sup.5 represents an aryl group or a heteroaryl group, X represents an oxygen atom, etc., and one of Q.sup.1, Q.sup.2, and Q.sup.3 represents a nitrogen atom and the other two represent CH); a salt of the derivative; and a drug containing the derivative or salt as the active ingredient. Due to strong PDE inhibitory action and TNF-.alpha. production inhibitory action, the derivative, salt, and drug are useful for the prevention and treatment of a wide variety of inflammatory diseases and autoimmune diseases.
摘要翻译： PCT No.PCT / JP97 / 03354 Sec。 371日期：1998年5月26日 102（e）日期1998年5月26日PCT 1997年9月22日PCT公布。公开号WO98 / 13348 日期：1998年4月2日本发明涉及由下式（1）表示的取代乙烯基吡啶衍生物：其中，R1表示氢原子，烷基等，R2表示烷基，R3和R4之一，彼此不同，表示氢原子，另一个表示腈基，R 5表示芳基或杂芳基，X表示氧原子等，Q 1，Q 2和Q 3中的一个表示氮原子，另外两个表示CH）; 衍生物的盐; 和含有衍生物或盐的活性成分的药物。由于强烈的PDE抑制作用和TNF-α产生抑制作用，衍生物，盐和药物可用于预防和治疗各种炎性疾病和自身免疫性疾病。

5. 发明授权

US5922767A Substituted benzylurea derivatives and medicine containing the same 失效
标题翻译：取代的苄基脲衍生物和含有它们的药物
公开(公告)号：US5922767A
公开(公告)日：1999-07-13
申请号：US946098
申请日：1997-10-07
申请人： Yoshihiko Kanamaru , Hiroyuki Hirota , Akihiro Shibata , Teruo Komoto , Hiroyuki Naito , Koichi Tachibana , Mari Ohtsuka , Fumio Ishii , Susumu Sato
发明人： Yoshihiko Kanamaru , Hiroyuki Hirota , Akihiro Shibata , Teruo Komoto , Hiroyuki Naito , Koichi Tachibana , Mari Ohtsuka , Fumio Ishii , Susumu Sato
IPC分类号： C07C275/28 , C07D213/30 , C07D307/42 , C07D333/16 , A61K31/17 , C07C275/06
CPC分类号： C07D213/30 , C07C275/28 , C07D307/42 , C07D333/16
摘要： Disclosed herein are substituted benzylurea derivatives represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.2 are independently H, a halogen atom, or an alkyl or alkoxyl group, R.sup.3 is a phenyl or heterocyclic group which may be substituted, n is an integer of 1-6, and R.sup.4 is a phenyl group which may be substituted, or salts thereof, and medicines comprising such a derivative as an active ingredient. The derivatives or salts thereof strongly inhibit only ACAT in macrophages and are hence useful as prophylactic and therapeutic agents for arteriosclerosis.
摘要翻译：本文公开了由以下通式（1）表示的取代的苄基脲衍生物：其中R 1和R 2独立地为H，卤素原子或烷基或烷氧基，R 3为可被取代的苯基或杂环基，n为 1-6的整数，R4是可被取代的苯基或其盐，以及包含这种衍生物作为活性成分的药物。其衍生物或盐在巨噬细胞中仅强烈地抑制ACAT，因此可用作动脉硬化的预防和治疗剂。

6. 发明授权

US5447926A Quinolone carboxylic acid derivatives 失效
标题翻译：喹诺酮羧酸衍生物
公开(公告)号：US5447926A
公开(公告)日：1995-09-05
申请号：US305977
申请日：1994-09-16
申请人： Fujiko Konno , Akihiro Shibata , Hideaki Matsuda , Takemitsu Asaoka , Ryuichi Kawahara , Naokata Taido , Tasdayuki Kuraishi , Sunao Takeda
发明人： Fujiko Konno , Akihiro Shibata , Hideaki Matsuda , Takemitsu Asaoka , Ryuichi Kawahara , Naokata Taido , Tasdayuki Kuraishi , Sunao Takeda
IPC分类号： A61K31/55 , A61P31/04 , C07D215/56 , C07D401/04 , C07D413/04 , C07D417/04 , C07D401/10 , C07D417/10
CPC分类号： C07D215/56 , C07D401/04 , C07D413/04 , C07D417/04
摘要： A quinolone carboxylic acid derivative having the following formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group, an aralkyl group, an ester residual group which can be hydrolyzed in living bodies, R.sup.2 is a hydrogen atom or an amino group which may be substituted by one or two lower alkyl groups, X is a hydrogen atom or a halogen atom, Y is CH.sub.2, O, S, SO, SO.sub.2, or N--R.sup.3, wherein R.sup.3 is a hydrogen atom or a lower alkyl group, and Z is an oxygen atom or two hydrogen atoms; or a salt thereof; and an antimicrobial agent comprising the same. The compound exhibits a superior antimicrobial activity, especially against gram positive microorganisms, and is thus useful for the treatments and prevention of various infectious diseases in clinics.
摘要翻译：具有下式（1）的喹诺酮羧酸衍生物，其中R1是氢原子，烷基，芳烷基，可在活体中水解的酯残基，R2是氢原子或可以被一个或两个低级烷基取代的氨基，X是氢原子或卤素原子，Y是CH 2，O，S，SO，SO 2或N-R 3，其中R 3是氢原子或低级烷基，Z为氧原子或两个氢原子; 或其盐; 和包含该抗微生物剂的抗微生物剂。该化合物具有优异的抗微生物活性，特别是抗革兰氏阳性微生物，因此可用于临床上各种感染性疾病的治疗和预防。

7. 发明授权

US5190951A Quinoline derivatives 失效
标题翻译：喹啉衍生物
公开(公告)号：US5190951A
公开(公告)日：1993-03-02
申请号：US773432
申请日：1991-10-09
申请人： Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
发明人： Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
IPC分类号： C07D219/06 , C07D221/16 , C07D401/06 , C07D471/04
CPC分类号： C07D401/06 , C07D219/06 , C07D221/16 , C07D471/04
摘要： Quinoline derivatives of the formula, ##STR1## wherein > A represents a group >N--(CH.sub.2).sub.n --, >C.dbd., >C.dbd.CH(CH.sub.2).sub.n --, or >CH(CH.sub.2).sub.n --, wherein n is an integer of 0-7; Y represents a group >C.dbd.O or >CHOH, R.sup.1 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group, R.sup.2 is a hydrogen atom, a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, a phenyl group which may have a substituent, a phenoxy group, an alkanoyloxy group, or an amino group which may have a substituent, R.sup.3 is a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group, and m is an integer of 1-3. The compounds and their salts exhibit a superior antiacetylcholinesterase activity with no side effects and are effective for the prevention or cure of senile dementia or memory disturbance.

8. 发明授权

US5164193A Sustained-release tablet 失效
标题翻译：可持续发布的平板电脑
公开(公告)号：US5164193A
公开(公告)日：1992-11-17
申请号：US732927
申请日：1991-07-19
申请人： Minoru Okada , Tetsuo Hayashi , Shuichi Kasai , Akira Iwasa
发明人： Minoru Okada , Tetsuo Hayashi , Shuichi Kasai , Akira Iwasa
IPC分类号： A61K9/20 , A61K9/22
CPC分类号： A61K9/2077
摘要： A sustained-release tablet is disclosed. The tablet is a combination of powder (A) comprising an oil component, water insoluble polymer, or both, and a pharmaceutically active component and powder (B) comprising a water soluble polymer and a pharmaceutically active component. An ideal release rate for individual pharmaceutically active component can easily be ensured by controlling its release rate by changing the ratio of powders (A) and (B).

9. 发明授权

US5100908A Antimycotic external imidazole preparations 失效
标题翻译：抗微生物外用咪唑烷制剂
公开(公告)号：US5100908A
公开(公告)日：1992-03-31
申请号：US650969
申请日：1991-02-05
申请人： Yutaka Murata , Takashi Narui , Tetsuo Kaneko , Takemitsu Asaoka , Katsumi Imamori , Akira Iwasa
发明人： Yutaka Murata , Takashi Narui , Tetsuo Kaneko , Takemitsu Asaoka , Katsumi Imamori , Akira Iwasa
IPC分类号： A61K31/415 , A61K33/08 , A61K33/10
CPC分类号： A61K33/10 , A61K31/415 , A61K33/08
摘要： Antimycotic external imidazole preparations are disclosed. They contain the following ingredients:(a) 0.1-5 wt. % of (E)-1-[2-methylthio-1-[2-(pentyloxy)phenyl]ethenyl]-1H-imidazole hydrochloride;(b) 0.01-3 wt. % of a basic substance; and(c) an external preparation base.

10. 发明授权

US5094851A Water-containing external preparations 失效
标题翻译：含水外用剂
公开(公告)号：US5094851A
公开(公告)日：1992-03-10
申请号：US577568
申请日：1990-09-05
申请人： Takashi Narui , Tetsuo Kaneko , Katsumi Imamori , Akira Iwasa
发明人： Takashi Narui , Tetsuo Kaneko , Katsumi Imamori , Akira Iwasa
IPC分类号： A61K9/06 , A61K20060101 , A61K9/00 , A61K9/107 , A61K31/57 , A61K47/06 , A61K47/10 , A61P17/00 , A61P29/00 , A61P37/08
CPC分类号： A61K9/0014 , A61K31/57 , A61K47/06 , A61K47/10 , Y10S514/969
摘要： Water-containing external preparations are disclosed, which contain, as essential ingredients, (a) 0.05-1 wt. % of deprodone propionate and (b) 1-20 wt. % of a polyhdric alcohol.
摘要翻译：公开了含水外用制剂，其含有（a）0.05-1wt。丙酸脱雄酮的百分比和（b）1-20重量％％的多酒精。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式